Outsourcing in Clinical Trials & Clinical Trial Supply East Asia 2021
Virtual Event: 8am CST / 9am KST-JST
30th November-1st December, 2021
Download Agenda
Outsourcing in Clinical Trials & Clinical Trial Supply East Asia 2021
The leading clinical Outsourcing conference in East Asia is returning on 30 Nov-1 Dec 2021. With a focus on providing delegates with practical take-aways and solutions to their most current operational and outsourcing challenges in clinical trials, this is an event not to be missed.
The 2020 conference was our most successful event to date, across the 2 days, delegates heard from some of the most innovative biopharmaceutical companies and service providers from across East Asia and further afield.
In 2021, not only will the audience be discussing clinical partnership and outsourcing challenges, but we also have the Clinical Trial Supply East Asia conference co-located with the event to give you the opportunity to define an end-to-end clinical strategy.
If you are interested in being involved in the 2021 conference, then please register your interest today
What to Expect for 2021?
Outsourcing in Clinical Trials & Clinical Trial Supply East Asia conference is the meeting place for the regional Life Sciences Industry – with over 30 hours of educational sessions and 2 stages this is the event to find ideas and inspiration for your trial needs
200+
ATTENDEES
30+
EXHIBITORS
25+
SPEAKERS
70%
ATTENDEES AT DIRECTOR + LEVEL
Why Attend
NETWORK
-
Over the course of 2 days of extensive networking breaks and social sessions, attendees will have the opportunity to make new connections and rediscover old contacts
LEARN
-
Delegates will listen and take part in over 20 learning sessions by leading biopharma from across East Asia. The programme will reflect the best in class case studies of clinical trial excellence leaving attendees inspired for their own studies
ACTION
-
The exhibition will feature 30 globally leading vendors with best in class solutions and ideas to solve your trial challenges and help you seize opportunities

Moon Hwan Kim
Chief Technical Officer,BiSiChem Korea
Biography:
Session Details: PANEL DISCUSSION: Clinical trials in Asia (Korea, China, Japan, Taiwan, India) 01-12-2021, 11:00 am View In Agenda

Vaibhav Choudhary
Joint Director- Medical and Clinical Affairs,Fresenius Kabi Oncology
Biography:
- A Clinical and Scientific Affairs professional with more than 14 years of experience in field of clinical trials and drug development and worked in various capacities .
- Started his career with well established global CRO in clinical QA field and later moved to sponsor end. Being on the both side (CRO and Sponsor), Vaibhav is well versed with Challenges on both side of fence.
- Currently, working with Fresenius Kabi Oncology as Joint director in Clinical and Medical Affairs function and based out of India. Managing the overall projects right from preclinical, clinical trial to regulatory registration phase. Handled various complex and multimillion dollar projects and successfully registered the various kind of products globally.
- Actively involved in CRO evaluation, selection and cross functional due diligence team for potential in-licensing opportunities .
Session Details: Risk-Based Monitoring and quality management: : An overview of Risk-Based approaches in clinical studies 30-11-2021, 1:45 pm View In Agenda

John Patava
Chief Operating Officer,AUM Biosciences Pte Ltd
Biography:
Session Details: Adaptive designs in clinical trials: their use in accelerating clinical development 30-11-2021, 12:45 pm View In Agenda

Agnes Jung
Sr. Director, Clinical development strategy,Bridge Biotherapeutics, Inc.
Biography:
Session Details: Local sponsor’s obligations in functional outsourced models 30-11-2021, 9:00 am View In Agenda

SeungAh Choe
Audit Manager,Clinical Quality Assurance, GSK
Biography:
Session Details: Decentralized Trials and the Pandemic/ Decentralized Trials & Technology 30-11-2021, 12:45 pm View In Agenda

Nari Yun
Executive Director, Clinical Development,GI Innovation Inc.
Biography:
Session Details: Utilizing CRO and vendors to maximize value of pipeline: clinical strategy guided by data 01-12-2021, 9:00 am View In Agenda

Rainbow Poon
Head of Strategic Business and Development Operations (SBDO),Merck China Healthcare
Biography:
Session Details: China Drug Development and Clinical Operations Considerations 01-12-2021, 10:30 am PANEL DISCUSSION: Clinical trials in Asia (Korea, China, Japan, Taiwan, India) 01-12-2021, 11:00 am View In Agenda

SangYoon Lee
CMO Head of oncology,Bridge Biotherapeutics
Biography:
Session Details: How a small biopharmaceutical venture organize multi-national clinical trial – balance between outsourcing and keeping core competency internally 30-11-2021, 10:00 am View In Agenda

Donghyun Park
CTO,Geninus Inc.
Biography:
Session Details: Development of Liquid Biopsy Technology in clinical trials 30-11-2021, 11:00 am Development of Liquid Biopsy Technology in clinical trial 30-11-2021, 1:15 pm CASE STUDY Sharing strategies for successful temperature management in IP/IMP management during transfer 30-11-2021, 1:45 pm View In Agenda

Jenny Choih
Director,Development/Medical Science Liaison, GENUV
Biography:
Session Details: CASE STUDY Strategies of Clinical Trials of CNS Therapeutics in US and East Asia 30-11-2021, 11:00 am View In Agenda

Soojin Rhee
Managing Director, ImmuneMed

Akhilesh Sharma
President & Chief Medical Officer,Alkem Laboratories
Biography: Dr. Akhilesh Sharma is M.D., in Clinical Pharmacology with further training in Clinical Research and Global Pharmacovigilance at Berkley Extension, California State University, USA and Luton Medical Centre, UK and is Fellow of Royal Liverpool hospital society-U.K.. He has more than 25 years of worldwide experience in areas of Clinical Research, Medical Affairs, Regulatory, Pharmacovigilance, Translation Medicine, Biomarkers, Clinical Pharmacology across various multinational pharmaceutical companies based at US & in India. He is currently President & Chief Medical Officer for Alkem Laboratories Ltd. He also co-founded biomarker research organization GeneXY in Philadelphia, USA jointly with Wistar institute, Pennsylvania university campus.
Session Details: Preparing global approval: How to navigate 505(b) 2 USFDA pathway in different scenarios 30-11-2021, 1:15 pm View In Agenda

Kumar Gaurav
Director & Cluster Head, Medical Affairs,Dr. Reddy's Laboratories
Biography: Dr. Kumar Gaurav is presently working as Director & Cluster Head, Medical Affairs in Dr Reddys Lab ,Hyderabad Kumar has 12+ years of Medical affairs experience including clinical experience across diversified sectors in Pharma Industry, health care and devices.In his previous roles,Kumar was with Allergan wherein he was Head-Medical Affairs, South Asia and Global Lead for Movement Disorders. Prior to Allergen he has worked with Baxter, Astra Zeneca and Ranbaxy in Medical Affairs & Clinical Research. He has a hands on experience in managing teams and handled therapy areas including Urology, Neurosciences, Devices, Anaesthesia, Critical care, Cardio-vascular, Metabolic & Anti-infectives. In his career of over 12+ years in pharma industry,Kumar was responsible for developing & executing Medical strategy,including flagship medical education programs, digital initiatives, consensus statements, global advisory board meetings for LCM and global evidence generation projects including optimal support in investigator initiated studies with a focus on treatment paradigms, and strategies for overcoming barriers to access and optimization of patient outcomes. Kumar has been significantly involved in building thought leader (TL) advocacy across organizations in India and Global regions and also in developing processes for facilitating the same. He has been involved in launch excellence with numerous successful launches to his credit in Cardiovascular and Neurology space-Crestor,Seloken XL,Plasmalyte ,Indications expansion of Botox therapuetics etc.He is also credited with successfully establishing & driving the Field Based Medical Affairs (MSL) Excellence in all organisations he worked with. As a part of his responsibility as a Clinical Research Team Lead, he was responsible for preparing clinical development plans for various NCEs – study designs and study conduct plans especially early phase studies and atypical generics. Overseeing the preparation and timely, quality delivery of Clinical Study Protocols, Clinical Study Reports for BE studies as well as phase I to IV clinical trials, for multi centric global clinical trials across various therapeutic areas, preparation of Clinical Overviews, Feasibility reports, Safety reports, PSURs. Faced International Regulatory Audits from various regions as ANVISA, USFDA, .DCGI and providing medical support for regulatory activities. An experienced medical writer, Kumar has over 20+ publications to his credit in various National & International Journals of repute including a book Chapter Kumar has done his MBBS from MGR University Chennai and his MD in Pharmacology & Therapeutics from Banaras Hindu University, Varanasi.
Session Details: Maximising the use of wearable Technologies and AI for a more patient centric approach 30-11-2021, 12:00 pm View In Agenda

Chunwon Jung
Team Head,Qurient, Inc

Lilian Chow
Vice President of Clinical Operations/Regulatory Affairs,Cerecin

Jungwon Jung
QA Director,CJ Health Care
Biography: 2001.09 ~ Present CJ HealthCare Quality Assurance & Technical development
- 1~Present
- Cell&Gene Therapy (Car-T) Project Team
- 06~2018.12
- New Plant Plan Project of Large Volume Parenteral
- TF team in strategic administration
- 09~
- Overseas CMO control by contact person
- New CMO business developments and technical transfer from Japan
- Analysis Lab
Session Details: View In Agenda

Jung Hwan Kim
General Manager,UNIMED

Arani Chatterjee
Senior Vice President, Clinical Research,Aurobindo Pharma
Biography:
Session Details: Sharing strategies for managing End-to-End pharmaceutical cold chain 01-12-2021, 10:00 am View In Agenda

Jaeyoul Cha
Blockchain Lab/R&D Manager,NDS
Biography:
Session Details: Healthcare Data Utilization and Privacy Protection 01-12-2021, 9:30 am View In Agenda

Brad Pruitt
Executive Medical Director, Digital Health,ICON
Biography:
- 20+ years In Clinical Research & Healthcare; 10+ years working as Executive in Digital Health
- Oversee Clinical6 strategy & solutions from protocol assessment through solution deployment
- Enjoys sports with water in all phases: surf, snowboard and ice hockey
- Mentor and Advisor for startup companies in San Diego (EvoNexus)
- Guest Lecturer and Contributing Author at UCSD’s Rady School of Management
- Located in San Diego, California (Pacific Time); PruittBrad@PRAHS.com; +1 (619) 813-7059
Session Details: Supporting Global Decentralized Clinical Trials (DCTs) with People, Processes & Technology 30-11-2021, 11:30 am Supporting Global Decentralized Clinical Trials (DCTs) with People, Processes & Technology 30-11-2021, 11:30 am View In Agenda

Laney Preheim
Vice President, Connected Health Services & Operations,ICON
Biography:
Laney Preheim has over 20 years in the high tech industry, with the majority of her career focused on the unique intersection between healthcare and technology. Ms. Preheim leads the global Concierge Services Coordinating Center (CSCC) which includes renowned offerings such as direct to patient services, site support, device logistics and patient safety surveillance and reporting. In this role, Ms. Preheim’s focus is to deeply consider the patient journey and the site staff’s study experiences as she provides world class assistance at each step along the way. Ms. Preheim is responsible for using real world services experience to define the strategic services roadmap.
Ms. Preheim joined ICON in 2021 through the acquisition of PRA Health Sciences. Prior nearly 10 years prior, she was on the leadership team at Care Innovations, a unique remote monitoring startup, of which she was a critical member of the formation team.
Ms. Preheim previously held a variety of positions at Intel Corporation in the Digital Health and Information Technology organizations, with focus on procurement, ecosystem enablement, product management and strategic planning. She has been at the forefront of managing organizational operations for the development of innovative strategies . Ms. Preheim is proud of her focus on team collaboration, building relationships and driving positive change across global lines. She earned a Bachelor of Business Administration degree from the University of California, Davis.
Session Details: Supporting Global Decentralized Clinical Trials (DCTs) with People, Processes & Technology 30-11-2021, 11:30 am Supporting Global Decentralized Clinical Trials (DCTs) with People, Processes & Technology 30-11-2021, 11:30 am View In Agenda

John Mann
Vice President, Decentralised Trials,
Biography: John Mann has more than 20+ years’ experience in clinical research organizations and 25 years in management including non-industry experience. He has managed studies that covered very large clinical trial project teams in over 50 countries with responsibilities for coordinating all clinical trial services. Additionally, Mr. Mann has extensive global pediatric and rare/ultra-rare clinical trial experience. Mr. Mann has work at multiple CROs and currently works at ICON (formally PRA Healthsciences) for the last 10 years where he has lead the emerging biotech and rare disease operations business sections in project management. During his time at ICON he helped lead the risk based monitoring task force and in early 2021 he moved to the newly formed Decentralized Trials (DCT) Operations business unit to help lead and operationalize DCT studies within ICON. He obtained his Project Management Professional Certification from the Project Management Institute (PMI), six sigma green belt certification from NC State University, change management certification from PROSCI, and has obtained is MSc degree from North Carolina State University
Session Details: Supporting Global Decentralized Clinical Trials (DCTs) with People, Processes & Technology 30-11-2021, 11:30 am Supporting Global Decentralized Clinical Trials (DCTs) with People, Processes & Technology 30-11-2021, 11:30 am View In Agenda

Catalent solves today’s clinical trial challenges and develop innovative solutions for the future. Catalent’s commitment to quality and service excellence is evident in its flexible solutions, modern global facilities, and over 25 years’ experience reliably supplying thousands of studies of all sizes and complexities around the world.





Cmed is Where Technology Meets Expertise. No other CRO is better prepared to support Biotech and Biopharma sponsors deliver the future of clinical trials.
Technology-led and with specialty expertise in oncology, cell & gene therapy, rare diseases, data science and analytics, we pioneered the processes for delivering next generation trials.
As the global pharmaceutical industry continues to undergo seismic change, our 20 years of innovation, commitment and expertise enable us to embrace radical disruption and transform the clinical trials landscape for the benefit of patients.
We anticipate. We adapt. We embrace every challenge. We are where you want to be.


Almac
Sponsorship opportunities
To enquire about sponsorship opportunities for the conference, please contact:
Nick McCudden
T: +61 280 978 126
E: NicholasMcCudden@arena-international.com
Speaker opportunities
The Outsourcing in Clinical Trials East Asia programme is written in collaboration with industry, if you would have a case study, idea or just a comment, please contact:
Chloe Roberts
Portfolio Director
T: +44 (0) 207 936 6822
E: chloe.roberts@arena-international.com